Sigyn Therapeutics, Inc. (SIGY)

OTCMKTS: SIGY · Delayed Price · USD
0.250
0.000 (-0.04%)
Jun 22, 2022 12:00 AM EDT - Market closed
-0.04%
Market Cap 9.32M
Revenue (ttm) n/a
Net Income (ttm) -3.22M
Shares Out 37.30M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Open 0.250
Previous Close 0.250
Day's Range 0.250 - 0.250
52-Week Range 0.146 - 1.300
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About SIGY

Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream. Sigyn Therapeutics, Inc. is headquartered in San Diego, California. [Read more...]

Industry Biotechnology
Founded 2019
Employees 5
Stock Exchange OTCMKTS
Ticker Symbol SIGY
Full Company Profile

News

Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board

SAN DIEGO, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated conditio...

Sigyn Therapeutics™ Appoints H. David Humes, MD to Its Scientific Advisory Board

SAN DIEGO, CA, March 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated condition...

Sigyn Therapeutics to Present at the Bullseye Small Cap Virtual Investor Conference

SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-related conditions that ...

Sigyn Therapeutics Announces Presentation at Today's Emerging Growth Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on the treatment of pathogen-related conditions that...

Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs ...

SAN DIEGO, Dec. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-related conditions that ...

Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated ...

In the Past Year, Sigyn Therapy™ Has Been Validated to Address a Broad-Spectrum of Inflammatory Mediators, Gram-Negative Bacterial Toxins, Gram-Positive Bacterial Toxins and Viral Pathogens

Sigyn Therapeutics Featured on National Public Radio: “Addressing the Cytokine Storm”

SAN DIEGO, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory c...

Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit

San Diego, California--(Newsfile Corp. - August 23, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit.  Ev...

Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory D...

SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of sepsis and other life-threateni...

Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study

SAN DIEGO, CA, July 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory ...

Sigyn Therapeutics Announces Rapid Elimination of Hepatic Toxins from Human Blood Plasma

SAN DIEGO, CA, July 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of sepsis and other life-threatenin...

Sigyn Therapeutics Reports Preliminary Results of Hepatic Encephalopathy Toxin Study

SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of sepsis and other life-threatening i...

The Evolution of Blood Purification Technologies to Treat Emerging Pandemic Threats, Including COVID-19

Webinar Event to Be Held Tomorrow June 29th at 12pm Eastern / 9am Pacific Time

Sigyn Therapeutics Announces Virtual Presentation Today at the LD Micro Invitational Conference

The Presentation Will Occur at 5:30pm Eastern / 2:30pm Pacific Time

Sigyn Therapeutics Announces Corporate Update Webinar

The Event Occurs Friday, May 21st at 11am Eastern / 8am Pacific Time

Sigyn Therapeutics™ Discloses In-Vitro Viral Pathogen Study

Sigyn Therapy™ demonstrates the ability to address viral pathogens, including SARS-CoV-2 (COVID-19)

The Closing Bell Featuring Sigyn Therapeutics

The Interactive Videoconference Occurs Today at 4pm Eastern / 1pm Pacific Time

Sigyn Therapeutics Announces Force Wealth Roundtable Forum with Goldman Small Cap Research

The Event Occurs Tomorrow, March 17th at 12pm Eastern / 9am Pacific Time

Sigyn Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory cond...

Sigyn Therapeutics Appoints Eric Lynam as Head of Clinical Affairs

Mr. Lynam to Oversee Clinical Studies of Sigyn Therapy™ to Treat Life-Threatening Inflammatory Conditions

Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. Discusses Treatment of Life-Threatening Conditions Induced...

Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - January 25, 2021) - Investorideas.com, a global news source and leading retail investor and trader resource issues a new CEO inte...

Recent Milestone Achievements of Sigyn Therapeutics Discussed During CEO Interview

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), disclosed today that its Chairman and CEO Jim Joyce is featured in an interview with The Wal...

Sigyn Therapeutics™ Reports Results of Pilot Study to Address Inflammatory CytoVesicles

Sigyn Therapy™ is a Candidate to Treat Life-Threatening Inflammatory Conditions That Are Not Addressed with Drug Therapies